Ambrisentan is therapeutically effective in improving exercise capacity and slowing disease progression in patients with pulmonary arterial hypertension (PAH).

Therapeutic Effect of Ambrisentan

Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH). It works by blocking endothelin-1, a potent vasoconstrictor that contributes to increased pulmonary vascular resistance. By inhibiting this pathway, Ambrisentan reduces pulmonary artery pressure, improves right ventricular function, and enhances exercise tolerance in patients with PAH. Its therapeutic effects are evident in delaying clinical deterioration and improving overall quality of life, particularly for patients suffering from advanced forms of the disease.